JAK inhibitors for the treatment of VEXAS syndrome.
Exp Biol Med (Maywood)
; 248(5): 394-398, 2023 05.
Article
in En
| MEDLINE
| ID: mdl-37243340
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a novel described autoinflammatory entity for which the diagnosis is defined by somatic mutations of the UBA1 X-linked gene in hematopoietic progenitor cells. The clinical manifestations are heterogeneous since they range from autoinflammatory symptoms to the presence of underlying hematologic disorders such as myelodysplastic syndromes. Response to treatment in VEXAS is very poor and to date, the therapeutic strategies adopted are only partially effective. However, recently described cohorts of subjects with VEXAS treated with Janus kinase inhibitors (JAK-I) proved that these drugs can be effective in the treatment of several manifestations related to the disease. Herein, we carried out a brief literature review that includes cohorts and single cases in which JAK-I were adopted as a promising strategy to manage VEXAS patients. Subsequently, we described our experience with JAK-I in VEXAS, illustrating the first case, to our knowledge, of a 65-year-old man who was successfully treated with the selective JAK-1 inhibitor filgotinib.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myelodysplastic Syndromes
/
Janus Kinase Inhibitors
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
Exp Biol Med (Maywood)
Journal subject:
BIOLOGIA
/
FISIOLOGIA
/
MEDICINA
Year:
2023
Document type:
Article
Affiliation country:
Italy
Country of publication:
United kingdom